CHICAGO (EGMN) - In the neoadjuvant setting, chemotherapy tends to be more effective than hormonal therapy at reducing tumor size in women with the luminal subtype of breast cancer, which generally has a better prognosis, new data show. Among 95 women with localized luminal breast cancer in a randomized phase II trial, two-thirds of those assigned to neoadjuvant chemotherapy had a response, compared with half of those assigned to neoadjuvant hormonal therapy, according to results reported at the...